Context Therapeutics Inc.
Clinical trials sponsored by Context Therapeutics Inc., explained in plain language.
-
New antibody takes aim at Hard-to-Treat cancers in first human trial
Disease control Recruiting nowThis early-stage trial is testing a new drug called CTIM-76 in people with advanced ovarian, testicular, or endometrial cancers that have not responded to standard treatments. CTIM-76 is a bispecific antibody designed to attach to a protein called Claudin-6 on cancer cells and he…
Phase: PHASE1 • Sponsor: Context Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug CT-95 targets tough cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new drug called CT-95 in people with advanced cancers that have a protein called mesothelin on their cells. The main goals are to find a safe dose and see if the drug can shrink tumors. About 70 adults with ovarian, lung, pancreatic, or other mesoth…
Phase: PHASE1 • Sponsor: Context Therapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC